Bladder Cancer Canada is seeking input from individuals with: 1) locally-advanced or metastatic bladder cancer (urothelial carcinoma), and/or 2) who have been treated with Keytruda (pembrolizumab).
The pan-Canadian Oncology Drug Review (pCODR) makes recommendations about whether provincial health plans should pay for new cancer drugs. pCODR will soon be reviewing the use of Keytruda (pembrolizumab) to treat locally-advanced or metastatic urothelial carcinoma. Bladder Cancer Canada will make a submission to ensure that patient voices are represented and considered during the review process. We would like to speak with patients about their experience.
Does this survey apply to you?
This survey is for patients with locally-advanced or metastatic urothelial carcinoma. Urothelial carcinoma is the most common form of bladder cancer.
It is also important to survey a subgroup of patients who have experience with Keytruda (pembrolizumab).
Caregivers may answer questions on behalf of the patient where the patient is unable or unavailable.
You do not need to live in Canada to respond to this survey; we appreciate input from every patient.
Important Deadline: Respond by February 24, 2019
The timeline to submit our feedback is very short. It is important you respond as quickly as possible.
Contact Tammy Northam, Executive Director at firstname.lastname@example.org or by calling 1-866-674-8889 if you would be willing to participate in a brief telephone interview.
Thank you for helping to ensure that patient experiences are represented in the cancer drug funding review process.